DRMA · Dermata Therapeutics, Inc. · Executive Compensation
$0.76
+0.00 (+0.28%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 11, 2026
Market Cap
$3.07M
Shares
4.02M
Volume · Nov 6
60.22K
Avg daily vol (3M)
3.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher J. Nardo | Senior Vice President, Chief Development Officer | $492,680 |
| Kyri K. Van Hoose | Senior Vice President, Chief Financial Officer | $464,616 |
| Gerald T. Proehl | President and Chief Executive Officer | $461,973 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher J. Nardo | Senior Vice President, Chief Development Officer | $469,970 |
| Kyri K. Van Hoose | Senior Vice President, Chief Financial Officer | $442,250 |
| Gerald T. Proehl | President and Chief Executive Officer | $392,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brittany Bradrick | Class II director | Appointed | 2026-05-27 |
| Steven Mento, Ph.D. | Class II director | Appointed | 2026-05-27 |
| David Hale | Class II director | Appointed | 2026-05-27 |
| Mary Fisher | Board of Directors | Resigned | 2026-02-25 |
| Kathleen Scott | Class III director | Appointed | 2024-05-07 |
| Wendell Wierenga, Ph.D. | Class III director | Appointed | 2024-05-07 |
| Gerald T. Proehl | Class III director | Appointed | 2024-05-07 |
| Brittany Bradrick | Class II director | Appointed | 2023-08-03 |
| David Hale | Class II director | Appointed | 2023-08-03 |
Leadership
- Gerald T. Proehl CEO, Board Member
- Kyri K. Van Hoose CFO
- Kyri Van Hoose CFO
- Andrew Sandler Board Member
- Brittany Bradrick Board Member
- David Hale Board Member
- Kathleen Scott Board Member
- Steven Mento Board Member
- Steven Mento, Ph.D. Board Member
- To approve Board Member
- Wendell Wierenga Board Member
- Wendell Wierenga, Ph.D. Board Member